KalVista Pharmaceuticals (KALV) Cash from Operations (QoQ) (2014 - 2025)
KalVista Pharmaceuticals (KALV) Cash from Operations (QoQ) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,184.45 Bn | 68,184.17 Bn | - |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 474.39 Bn | 469.59 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.21 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.43 Bn | 63.43 Bn | - |
| 8 | Argenx Se | 56.67 Bn | 51.49 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 38.08 Bn | 38.08 Bn | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -35.03% |
| Oct 31, 2024 | 1.44% |
| Jul 31, 2024 | -166.27% |
| Apr 30, 2024 | 45.21% |
| Jan 31, 2024 | -39.07% |
| Oct 31, 2023 | 25.83% |
| Jul 31, 2023 | -18.09% |
| Apr 30, 2023 | -143.69% |
| Jan 31, 2023 | 54.89% |
| Oct 31, 2022 | 9.45% |
| Jul 31, 2022 | 15.11% |
| Apr 30, 2022 | -90.47% |
| Jan 31, 2022 | 28.04% |
| Oct 31, 2021 | -10.21% |
| Jul 31, 2021 | -60.57% |
| Apr 30, 2021 | -45.60% |
| Jan 31, 2021 | 4.60% |
| Oct 31, 2020 | -121.63% |
| Jul 31, 2020 | 71.56% |
| Apr 30, 2020 | 3.75% |